Empagliflozin for fluid buildup from cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have cirrhosis with ascites and are on a stable water-pill plan (spironolactone, and sometimes a loop diuretic) without needing a large belly-drain
- Your kidney function is good enough for the study (eGFR is 30 or higher)
- Your blood pressure is not too low (systolic is at least 100)
- Your bilirubin (direct bilirubin) is less than 3 mg/dL
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two heart medications, carvedilol and empagliflozin, to see if they improve heart function in people with cirrhosis (liver scarring). It might help those who have early signs of heart stiffness but normal pumping strength.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This study tests a medication called dapagliflozin (a drug used for diabetes) to see if it can help people with advanced liver disease and fluid build-up in the belly that does not go away with standard care. It may offer a new way to manage this difficult condition.
This trial tests a diabetes pill (dapagliflozin) to see if it helps people with liver cirrhosis and fluid buildup (ascites). The goal is to improve fluid balance and possibly reduce hospital stays.
This trial tests if a diabetes medicine called empagliflozin can help people with Fontan circulatory failure feel better and do more of their daily activities.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.